Rockefeller Capital Management
ATXS

Rockefeller Capital Management’s Astria Therapeutics ATXS Stock Holding History

Rockefeller Capital Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-6,462
Closed -$84.6K – 4699
2025
Q4 		$84.6K Buy
+6,462
New +$77.2K ﹤0.01% 2797

Rockefeller Capital Management's ATXS Position: Q1 2026 in Review

Rockefeller Capital Management sold out of Astria Therapeutics (ATXS) in Q1 2026, closing a stake of 6,462 shares — an estimated $84.6K sold.

Rockefeller Capital Management first reported a position in ATXS in Q4 2025 and held it in 1 quarter. The position peaked at $84.6K in Q4 2025. 0 funds tracked by Wall St. Rank hold ATXS as of Q1 2026.

  • Rockefeller Capital Management reported no remaining Astria Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Rockefeller Capital Management sold 6,462 Astria Therapeutics shares in Q1 2026, an estimated $84.6K.
  • Rockefeller Capital Management first reported a position in Astria Therapeutics in Q4 2025 and held it in 1 quarter.
  • Rockefeller Capital Management's Astria Therapeutics position peaked at $84.6K in Q4 2025.
  • 0 funds tracked by Wall St. Rank held Astria Therapeutics as of Q1 2026.

Based on Rockefeller Capital Management's 13F filing for Q1 2026, filed 14 May 2026.